shlok, thanks for bringing all these future possibilities here. Iron overload in different tissues, cells, and their mitochondria is a huge problem. IMO, First ATH needs to get ATH434 to the market and then target new indications with big possibilities they already have experimental data as traumatic brain injury, Alzheimer's, etc. But with 11 full-time people in the company expansion to these areas is difficult. So, after FED has proven ATH434, there will be a big pharma deal, IMO, to start working with these new indications with many more people in the company.
shlok, thanks for bringing all these future possibilities here....
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $31.47M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.6¢ | 0.5¢ | $1.154K | 220.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 72 | 68217577 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 5645561 | 13 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.6¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.6¢ | 0.6¢ | 0.6¢ | 100511 | ||
| Last updated 15.58pm 02/05/2024 ? | |||||
| ATH (ASX) Chart |